FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia
(fda.gov)
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.
Exploding Head Syndrome: What We Know About This Mysterious Disorder
(sciencealert.com)
Have you ever been drifting off to sleep, only to be jerked awake by the sound of a bomb going off inside your head? If you have, then you have most likely experienced exploding head syndrome, a mysterious and poorly understood sleep disorder.
Have you ever been drifting off to sleep, only to be jerked awake by the sound of a bomb going off inside your head? If you have, then you have most likely experienced exploding head syndrome, a mysterious and poorly understood sleep disorder.